CAS 79712-55-3

Tazifylline

Description:

Tazifylline, with the CAS number 79712-55-3, is a chemical compound that belongs to the class of xanthine derivatives. It is primarily recognized for its pharmacological properties, particularly as a bronchodilator, which makes it useful in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The compound exhibits anti-inflammatory effects and may enhance mucociliary clearance, contributing to improved respiratory function. Tazifylline's mechanism of action involves the inhibition of phosphodiesterase enzymes, leading to increased levels of cyclic AMP, which promotes relaxation of bronchial smooth muscle. In terms of physical characteristics, Tazifylline is typically a white to off-white crystalline powder, with moderate solubility in water and organic solvents. Its stability and reactivity can vary based on environmental conditions, such as pH and temperature. As with many pharmacological agents, safety and efficacy profiles are essential, and ongoing research continues to explore its potential therapeutic applications and side effects.

Formula: C₂₃H₃₂N₆O₃S

InChI: InChI=1/C23H32N6O3S/c1-25-21-20(22(31)26(2)23(25)32)29(17-24-21)16-18(30)15-28-12-10-27(11-13-28)9-6-14-33-19-7-4-3-5-8-19/h3-5,7-8,17-18,30H,6,9-16H2,1-2H3

SMILES: Cn1c2c(c(=O)n(C)c1=O)n(CC(CN1CCN(CCCSc3ccccc3)CC1)O)cn2

Synonyms:

• Tazifylline [INN]
• Tazifilina
• Tazifilina [Spanish]
• Tazifyllinum
• Tazifyllinum [Latin]
• Unii-F45Ox6Fzwp
• 1H-Purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-
• 7-(2-hydroxy-3-{4-[3-(phenylsulfanyl)propyl]piperazin-1-yl}propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione

(±)-Tazifylline

CAS: 79712-55-3

(±)-Tazifylline

Purity: ≥98%

Molecular weight: 472.6g/mol

Ref: 54-BUP14297

Tazifylline

Controlled Product

CAS: 79712-55-3

Tazifylline is an anti-inflammatory drug that belongs to the group of non-steroidal anti-inflammatory drugs. It is a racemic mixture of two enantiomers, (+)-tazifylline and (-)-tazifylline, which have different pharmacological properties. Tazifylline has been shown to inhibit leukotriene synthesis by competitive inhibition of leukotriene receptors. This drug also inhibits the production of bronchial reactivity in guinea pigs as well as the development of idiopathic urticaria in humans. Tazifylline has a terminal half-life of 2 hours and is administered orally or intravenously at a dosage between 50 and 100 mg/day.

Formula: C₂₃H₃₂N₆O₃S

Purity: Min. 95%

Molecular weight: 472.6 g/mol

Ref: 3D-EDA71255

(±)-Tazifylline

CAS: 79712-55-3

(±)-Tazifylline is a selective and long-acting antagonist of histamine H1 receptor.

Formula: C₂₃H₃₂N₆O₃S

Purity: 99.54%

Color and Shape: Solid

Molecular weight: 472.6

Ref: TM-T10000